MARKET

TNXP

TNXP

Tonix Pharmaceut
NASDAQ
15.62
-0.20
-1.26%
After Hours: 15.95 +0.33 +2.11% 19:58 12/31 EST
OPEN
15.80
PREV CLOSE
15.82
HIGH
16.11
LOW
15.47
VOLUME
606.59K
TURNOVER
--
52 WEEK HIGH
69.97
52 WEEK LOW
6.76
MARKET CAP
199.75M
P/E (TTM)
-0.7769
1D
5D
1M
3M
1Y
5Y
1D
Tonix Pharmaceuticals 13G Filing Shows Point72 Asset Management Reported A 9.2% Stake In The Co As Of December 29, 2025
Benzinga · 12/31/2025 21:14
POINT72 ASSET MANAGEMENT LP REPORTS 9.2% PASSIVE STAKE IN TONIX PHARMACEUTICALS AS OF DEC 29 - SEC FILING
Reuters · 12/31/2025 21:13
Tonix Pharma Announces $20 Million Registered Direct Offering
TipRanks · 12/29/2025 21:58
Tonix Pharmaceuticals Holding Corp. publishes monoclonal antibody prevention data for Lyme disease
Reuters · 12/29/2025 21:19
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026
Benzinga · 12/29/2025 17:11
BUZZ-Tonix Pharmaceuticals ticks up after $20 million direct stock deal
Reuters · 12/29/2025 13:22
Tonix Pharma advances TNX-4800 Lyme disease program
TipRanks · 12/29/2025 13:18
TONIX PHARMACEUTICALS SHARES FALL 6.4% PREMARKET AFTER CO PRICES STOCK AND WARRANT OFFERING
Reuters · 12/29/2025 13:02
More
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Webull offers Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ: TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.